What is the most effective and simplest oral suppressive regimen for a methicillin‑sensitive Staphylococcus aureus prosthetic joint infection when definitive surgical cure is not possible?

Best Oral Suppressive Regimen for MSSA Prosthetic Joint Infection

For MSSA prosthetic joint infection requiring chronic suppression, use oral cephalexin or dicloxacillin as first-line monotherapy based on IDSA guidelines 1.

Primary Recommendation

The IDSA guidelines explicitly recommend indefinite chronic oral antimicrobial suppression with cephalexin, dicloxacillin, co-trimoxazole, or minocycline for staphylococcal PJI when definitive surgical cure is not possible 1. For MSSA specifically, the simplest and most effective options are:

• First-generation cephalosporins (cephalexin) - easiest with excellent MSSA coverage
• Antistaphylococcal penicillins (dicloxacillin) - equally effective alternative
• Co-trimoxazole - if penicillin allergy or intolerance exists
• Tetracyclines (doxycycline/minocycline) - alternative option

Key Algorithmic Approach

Step 1: Verify Prior Treatment

Ensure the patient has completed appropriate initial therapy (2-6 weeks IV therapy ± rifampin combination if debridement was attempted) 1. Critical caveat: Patients with an antibiotic-free period before starting suppression have significantly higher failure rates (83% in one study) 2.

Step 2: Select Suppressive Agent

For MSSA, prioritize in this order:

1. Cephalexin (simplest, best tolerated, excellent MSSA activity)
2. Dicloxacillin (if cephalexin unavailable)
3. Co-trimoxazole (if β-lactam allergy)
4. Doxycycline/minocycline (alternative with reasonable efficacy)

Step 3: Avoid These Pitfalls

• Never use rifampin alone for chronic suppression 1
• Rifampin combination therapy is NOT generally recommended for suppression (only one panelist uses it in selected situations) 1
• Avoid fluoroquinolones for MSSA suppression - they are reserved for rifampin companion therapy during active treatment, not chronic suppression

Evidence Supporting This Approach

The IDSA guideline framework is clear that suppression follows the initial treatment phase and uses different agents 1. Real-world data supports this strategy:

• Overall success rates: 56-67% of patients achieve infection control with suppressive therapy 3, 2
• MSSA-specific challenge: S. aureus infections have notably higher failure rates (80% in one study) compared to other organisms (33%) 2, making agent selection critical
• Tetracycline experience: When doxycycline was used for suppression, 72% remained controlled with 18% adverse events 4
• Monotherapy preferred: 67% of patients in the largest cohort received monotherapy successfully 3

Duration and Monitoring

• Duration: Indefinite suppression is required 1
• Monitoring: Clinical and laboratory monitoring for both efficacy (symptoms, inflammatory markers) and toxicity is advisable 1
• Adverse events: Expect 5-18% discontinuation rates due to side effects 3, 4

Patient Selection Considerations

Suppressive therapy is most successful in:

• Patients ≥70 years old (younger patients have 1.6× higher failure risk) 3
• Standard prostheses (90% success vs 50% for tumor prostheses) 5
• Lower extremity joints (upper limb has 2.4× higher failure risk) 3

The decision must weigh the risks of prolonged antibiotic therapy against progressive implant loosening and bone stock loss 1. This approach is reserved for patients unsuitable for or refusing further surgical intervention.